fda warning letters compounded semaglutide tirzepatide 2025 glp-1 compounding october Pharmacovigilance Assessment of GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System New project announcement: HHS‑OIG is

Purpose-built for physicians Q&A: Liraglutide outperforms colesevelam in reducing stool frequency in bile acid diarrhea Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology

Interstitial Cystitis is a clinical diagnosis characterized by irritative bladder symptoms such as urinary urgency, frequency, and hesitancy in the absence of infection

Your dose-response curves will be skewed, your results will be weak or nonexistent, and your conclusions will be built on a faulty foundation

BPC-157 does not simply mask symptoms or temporarily reduce inflammation